Regulus Therapeutics (RGLS) Shares Gap Down to $0.85
Regulus Therapeutics Inc (NASDAQ:RGLS) shares gapped down prior to trading on Friday . The stock had previously closed at $0.50, but opened at $0.85. Regulus Therapeutics shares last traded at $0.92, with a volume of 1920827 shares changing hands.
RGLS has been the topic of a number of recent research reports. Zacks Investment Research lowered shares of Regulus Therapeutics from a “buy” rating to a “hold” rating in a research note on Thursday, January 25th. Chardan Capital reaffirmed a “neutral” rating on shares of Regulus Therapeutics in a research note on Tuesday, January 16th. Needham & Company LLC reaffirmed a “hold” rating on shares of Regulus Therapeutics in a research note on Tuesday, November 14th. Leerink Swann initiated coverage on shares of Regulus Therapeutics in a research note on Friday, January 5th. They issued an “outperform” rating and a $2.00 price objective on the stock. Finally, BMO Capital Markets set a $1.00 price objective on shares of Regulus Therapeutics and gave the company a “hold” rating in a research note on Thursday. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and two have given a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and a consensus price target of $2.20.
The company has a debt-to-equity ratio of 0.41, a current ratio of 6.77 and a quick ratio of 6.77.
Several institutional investors and hedge funds have recently added to or reduced their stakes in RGLS. BVF Inc. IL lifted its position in shares of Regulus Therapeutics by 7.9% during the fourth quarter. BVF Inc. IL now owns 13,974,249 shares of the biopharmaceutical company’s stock valued at $14,533,000 after purchasing an additional 1,025,020 shares in the last quarter. Ascend Capital LLC bought a new position in shares of Regulus Therapeutics during the fourth quarter valued at about $1,053,000. Candriam Luxembourg S.C.A. bought a new position in shares of Regulus Therapeutics during the third quarter valued at about $750,000. South Dakota Investment Council lifted its position in shares of Regulus Therapeutics by 37.1% during the third quarter. South Dakota Investment Council now owns 1,820,027 shares of the biopharmaceutical company’s stock valued at $2,275,000 after purchasing an additional 492,969 shares in the last quarter. Finally, Victory Capital Management Inc. bought a new position in shares of Regulus Therapeutics during the third quarter valued at about $347,000. 53.72% of the stock is currently owned by institutional investors.
Regulus Therapeutics Company Profile
Regulus Therapeutics Inc is a biopharmaceutical company focused on discovering and developing drugs that target microRNAs to treat a range of diseases. The Company uses its microRNA product platform to develop chemically modified, single-stranded oligonucleotides that the Company calls anti-miRs to modulate microRNAs and return diseased cells to their healthy state.
Receive News & Ratings for Regulus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regulus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.